Amicus Therapeutics, Inc. $FOLD Shares Bought by Invesco Ltd.

Key Points

• Invesco Ltd. increased its stake in Amicus Therapeutics by 4.1%, acquiring an additional 105,856 shares, bringing their total ownership to approximately 2.66 million shares valued at $21.7 million.
• A number of institutions have made significant moves regarding Amicus Therapeutics shares, including GAMMA Investing LLC, which raised its holdings by over 1,610% in the first quarter.
• Analyst ratings for Amicus Therapeutics vary, with Morgan Stanley upgrading the stock to "overweight" while others, like Goldman Sachs, lowered their price target from $12 to $9, leading to a current consensus rating of "Moderate Buy."

Invesco Ltd. raised its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 4.1% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,661,394 shares of the biopharmaceutical company's stock after acquiring an additional 105,856 shares during the quarter. Invesco Ltd. owned approximately 0.86% of Amicus Therapeutics worth $21,717,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in FOLD. Virtus Fund Advisers LLC acquired a new position in shares of Amicus Therapeutics in the fourth quarter worth $29,000. PNC Financial Services Group Inc. raised its holdings in shares of Amicus Therapeutics by 211.4% in the first quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company's stock worth $42,000 after acquiring an additional 3,497 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Amicus Therapeutics in the fourth quarter worth $59,000. GAMMA Investing LLC raised its holdings in shares of Amicus Therapeutics by 1,610.8% in the first quarter. GAMMA Investing LLC now owns 7,442 shares of the biopharmaceutical company's stock worth $61,000 after acquiring an additional 7,007 shares during the last quarter. Finally, Bryce Point Capital LLC acquired a new position in shares of Amicus Therapeutics in the first quarter worth $100,000.

Amicus Therapeutics Price Performance

FOLD stock opened at $7.40 on Thursday. The stock has a 50-day moving average price of $6.29 and a two-hundred day moving average price of $7.23. Amicus Therapeutics, Inc. has a 12-month low of $5.51 and a 12-month high of $12.65. The company has a current ratio of 3.21, a quick ratio of 2.29 and a debt-to-equity ratio of 1.92. The company has a market cap of $2.28 billion, a PE ratio of -61.66 and a beta of 0.53.

Analyst Ratings Changes

A number of brokerages have recently commented on FOLD. Morgan Stanley raised Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a research report on Thursday, July 17th. The Goldman Sachs Group lowered their price objective on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. Wall Street Zen raised Amicus Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Finally, UBS Group lifted their price objective on Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Eight analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat, Amicus Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $16.22.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.